Steven Miller - Catalyst Pharmaceuticals COO and Chief Scientific Officer

CPRX Stock  USD 23.09  0.47  2.08%   

COO

Dr. Steven R. Miller, Ph.D. is Chief Operating Officer, Chief Scientific Officer of Catalyst Pharmaceutical Partners Inc. He has served as Chief Operating Officer since January 2011 and as our Chief Scientific Officer since October 2009. Previously, commencing in April 2007, Dr. Miller was our Vice President of Pharmaceutical Development and Project Management. Dr. Miller has worked in the healthcare industry for over 30 years. Prior to joining us, Dr. Miller spent 15 years with various divisions of Watson Laboratories, a subsidiary of Watson Pharmaceuticals, Inc., most recently as Executive Director of RD Operations. In this capacity, Dr. Miller managed a team of 75 in the testing of all RD products for clinical trials, including method valuation, stability testing, operation of the RD pilot plant, and assembly of the CMC section of drug applications, in addition to other responsibilities. Prior to holding this position, Dr. Miller was Director of Technology Transfer for Watson Laboratories, and Vice President of Research and Product Development for Royce Laboratories, which was subsequently acquired by Watson Laboratories. Prior to joining Royce Laboratories, Dr. Miller was Group Leader and Senior Scientist at Dade Behring. Prior to that, he served as an Analytical Chemist at the U.S. Food Drug Administration since 2011.
Age 63
Tenure 14 years
Professional MarksPh.D
Address 355 Alhambra Circle, Coral Gables, FL, United States, 33134
Phone305 420 3200
Webhttps://www.catalystpharma.com
Miller received his BS Degree in Chemistry from the University of Maryland and his Ph.D. from the University of Miami.

Steven Miller Latest Insider Activity

Tracking and analyzing the buying and selling activities of Steven Miller against Catalyst Pharmaceuticals stock is an integral part of due diligence when investing in Catalyst Pharmaceuticals. Steven Miller insider activity provides valuable insight into whether Catalyst Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Catalyst Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Catalyst Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Catalyst Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.1835 % which means that it generated a profit of $0.1835 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2829 %, meaning that it created $0.2829 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Catalyst Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.21 in 2025, whereas Return On Assets are likely to drop 0.14 in 2025. At this time, Catalyst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 264.8 M in 2025, whereas Other Assets are likely to drop 1.09 in 2025.
Catalyst Pharmaceuticals currently holds 3.56 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Catalyst Pharmaceuticals has a current ratio of 10.57, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Catalyst Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 3 records

COO Age

Matthew WintonInozyme Pharma
47
MBA IIDay One Biopharmaceuticals
48
Seokho EsqTerns Pharmaceuticals
46
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 76 people. Catalyst Pharmaceuticals (CPRX) is traded on NASDAQ Exchange in USA. It is located in 355 Alhambra Circle, Coral Gables, FL, United States, 33134 and employs 167 people. Catalyst Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Catalyst Pharmaceuticals Leadership Team

Elected by the shareholders, the Catalyst Pharmaceuticals' board of directors comprises two types of representatives: Catalyst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalyst. The board's role is to monitor Catalyst Pharmaceuticals' management team and ensure that shareholders' interests are well served. Catalyst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalyst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Philip Schwartz, Co Sec
CMA CPA, VP, Officer
Pete Sr, Vice Sales
Richard MBA, CEO President
Mary Coleman, VP Relations
Stanley MD, Senior Discovery
Gary MD, Chief Officer
Jeffrey Carmen, Executive Officer
Michael CPA, Executive CFO
Preethi Sundaram, Chief Officer
Patrick McEnany, Co-Founder, Chairman, CEO and Pres
Steven Miller, COO and Chief Scientific Officer
Brian JD, Chief Officer

Catalyst Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalyst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.